Calmare Therapeutics Incorporated Uplists
May 23, 2016
Trading on the OTCQB Begins Today at Market Open

Fairfield, CT – May 23 2016 – Calmare Therapeutics Incorporated, (OTC: CTTC) (CTI), the pain mitigation company, effective today at Market open, CTTC will be quoted on the "OTCQB."

"CTI is showing progress," said CTI President & CEO Conrad Mir. "Over the past four months, we gained a $15 million general supply order contract giving the Company a separate and distinct revenue stream from its flagship Calmare® Pain Therapy device; consecutive quarters of timely, filing compliance; and now, uplisted to the 'qb.' Management strongly believes 2016 will be one of the most significant and eventful years for the Company."

About the Company

Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy company, researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. Our flagship medical device - the Calmare® Pain Therapy Device - is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation (K081255) on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United. Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations via CTI’s General Services Administration (GSA) military contract (V797P-4300B).

Forward-Looking Statement

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Direct inquiries to
Conrad F. Mir
Calmare Therapeutics Incorporated
2 Trap Falls Rd. STE 507
Shelton, CT 06484
Email: This email address is protected. Javascript must be enabled to view it.
Tel: 203.712.7893